WILMINGTON, Mass., March 12, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today its QS-H150 handheld explosives trace detector has received an important regulatory certification in China from the Chinese Ministry of Public Security. This marks the latest in a series of key product certifications for Implant Sciences, including STAC in France and TSA’s qualification for air cargo screening in the US.

Implant Sciences has been active in the China market for several years. China represents an important market for the Company, one where it has generated over $20 million in sales to date. Its explosives trace detectors have been deployed at the 2008 Beijing Olympics, Beijing subway stations, and are in use for aviation security and critical infrastructure protection. In July 2013, the Company opened a representative office in Shanghai.

“This Ministry of Public Security certification opens the doors for us to compete for additional public security contracts issued by the Chinese government. We believe this will significantly expand our sales opportunities in China, where we already have a strong presence and our products have a stellar reputation for performance and cost efficiency,” stated Glenn D. Bolduc, Implant Sciences’ President and CEO.

Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones, added, “The results of these stringent certification tests further demonstrate the strength of our QS-H150. Notable accomplishments in the testing were the very rapid clear-down time, which is essential for high traffic screening areas, the large number and variety of explosives detected at minute levels, and the system’s performance in a wide range of temperatures and environments.”

BOTHELL, WA–(Marketwired – Mar 10, 2014) – Borneo Resource Investments Ltd. (OTCQB: BRNE) (the “Company” or “Borneo”), a mining company that mines gold and develops producing gold mines as well as coal mining properties in Indonesia, today announced it has begun full production on its Ratatotok South gold property. Ratatotok South, which was acquired through Borneo’s subsidiary PT Puncak Kalabat in December 2013, becomes the Company’s second producing gold mine.

Two successful test runs were completed at Ratatotok South in January and February, setting the stage for full production to begin in March. Approximately 2,500 metric tons of high grade ore have been excavated in the last few weeks and positioned in the heapleach containment area. Up to three processing cycles will be run on the ore to extract all of the gold it contains. At the end of each processing cycle the ore enhanced carbon will be moved from the site to the Company’s facilities in Manado for final processing.

“I am very pleased that we were able to move from acquisition, through the processing trials and to full production at Ratatotok South so quickly. Our team was able to fine tune the production process during the trials and our geologists supervised the excavation of a high grade ore body on the property for our first production run,” commented Borneo CEO Nils Ollquist.

Mr. Ollquist went on to say, “Our geologists estimate the ore grade to be 2 to 3 grams of gold per metric ton. The estimated production output from 2,500 metric tons of ore for the first full production run is approximately 7 kg of 80% pure gold. Our intention is to continue to upgrade and refine our production capabilities and to expand our portfolio of high quality properties in the area.”

About Borneo Resource Investments Ltd.

Borneo Resource Investments Ltd. (OTCQB: BRNE) is a mining company that mines gold and develops producing gold mines as well as coal mining properties in the Republic of Indonesia. Borneo’s current assets include three gold properties, two of which are producing gold. Cash flow-producing investments in gold properties help fund Borneo’s operations and investments in gold, while the Company develops high value, longer-term investments in thermal “coal concessions,” which are properties that can be mined for coal. Borneo currently has one coal concession in the Borneo region of Indonesia. Indonesia was the 8th largest gold producing nation in 2012 and the world’s largest exporter of coal, with $25 billion exported in 2012.

JERUSALEM, March 11, 2014 /PRNewswire/ — Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government’s patent office, has issued the Company its third patent in the country. The patent, titled “Methods and Compositions for Oral Administration of Exenatide,” covers oral exenatide compositions made using the company’s proprietary technology, including its ORMD-0901 oral exenatide capsule.

Oramed has planned a comprehensive clinical program for ORMD-0901, with the goal of seeking approval in the U.S. and other territories. IND-enabling toxicity studies are scheduled to begin later this year in the U.S. and a Phase 1b study outside of the U.S. is also planned for 2014.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral GLP-1 analog capsule (ORMD-0901). Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company’s corporate and R&D headquarters are based in Jerusalem.

ROCKVILLE, Md.–(BUSINESS WIRE)–

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

The study is still ongoing and the maximal tolerated dose (MTD) has not yet been achieved. Three dosing cycles have been completed (25, 50 and 100 mg) and no drug related adverse events have been reported. The fourth dosing cycle (150 mg) has been initiated. Two patients have received 2 cycles of treatment and one patient has received 6 cycles of treatment. Pharmacokinetic analysis has shown that SupinoxinTM displays dose-proportional exposure and an estimated oral bioavailability of 51%. The pharmacokinetic profile of Supinoxin is similar to what has been seen in preclinical studies.

Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer commented, “We are encouraged that Supinoxin is safe and well-tolerated over the dose range tested in cancer patients with solid tumors who have received multiple cycles of treatment. In addition, the pharmacokinetic profile and oral bioavailability of Supinoxin is consistent with preclinical studies. These data are very encouraging, and we look forward to sharing additional data from the trial when it is completed later this year.”

The Phase I trial of Supinoxin, which was initiated in August 2013, is a dose-escalation study which will evaluate the safety, tolerability, dose-limiting toxicities and MTD in patients with solid cancer tumors that have previously failed treatment with approved therapies and shown progression of disease. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. This trial is being conducted in three clinical oncology centers in the United States. Each patient has the ability to continue on the drug up to six cycles of treatment (a dosing cycle is defined as 3 weeks of drug treatment followed by and 1 week off) if no disease progression is seen. Patients are assessed by CT or MRI prior to the start of therapy and after every two cycles of therapy to assess tumor progression. The trial is using an accelerated dose-escalation design: one patient is treated per dose cycle until a grade 2 related adverse event occurs then three patients will be treated per dose cycle. The decision to escalate dose is made by the DMSB after completion of one cycle of treatment based on safety and tolerability. Patients have the possibility to receive up to 6 cycles of treatment if the disease does not progress. Tumor biopsy samples are taken to assess the biomarker phospho-P68.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. The trial is already active in dozens of hospitals and clinical centers in 12 countries.

21st Century Oncology is the largest global, physician-led provider of integrated cancer care services, operating 166 treatment centers, with 133 centers in 16 U.S. states and 33 centers in six Latin American countries. The Greenville, North Carolina facility is led by Dr. Ron Allison, a board-certified radiation oncologist specializing in Head and Neck Cancer. Dr. Allison, who is serving as the Principal Investigator of CEL-SCI’s Phase III study at the site, has authored several books in the field of oncology and holds several patents addressing radiation isometer measurement devices/visualization and ultrasound distance measurement devices.

“Our goal is to have between 10 and 15 U.S. clinical centers participating in our Phase III trial. We should be there by this summer.” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine

Multikine (Leukocyte Interleukin, Injection) is an immunotherapeutic agent that is being tested in a randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI’s clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body’s natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100-110 clinical centers in about 20 countries.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the US Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also announced that it entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

WILMINGTON, Mass., March 5, 2014 /PRNewswire/ — Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that officials from the United States Transportation Security Administration (TSA) and the Canadian Air Transport Security Authority (CATSA) toured Implant Sciences’ headquarters and 58,000 sq. ft. manufacturing facility in Wilmington, Massachusetts on Tuesday, January 28, 2014.

TSA and CATSA work together in a partnership to explore existing and new technologies. During the tour, officials met with Implant Sciences’ executives and staff and learned about the manufacturing processes of the QS-B220 and QS-H150 explosives trace detectors (ETD), which are currently used around the world in mission critical security applications. The Company also provided updates on new ETD technologies being developed for future applications.

Implant Sciences President and CEO, Glenn Bolduc, commented, “We were pleased to have the opportunity to host officials from the TSA and CATSA. These agencies play a critical role in keeping passengers and aviation facilities safe. This visit was an opportunity to demonstrate to some of the biggest security equipment procurers in the world that Implant Sciences is a small business that can deliver quality security technology. We trust that they were impressed by our state-of-the-art manufacturing facility and by the caliber of our personnel.”

The Company’s QS-B220 desktop ETD has received TSA qualification for air cargo screening and is currently is in the final stages of TSA qualification for checkpoint and checked baggage screening.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company’s QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for “Best Explosives Detection Solution”. For further details on the Company and its products, please visit the Company’s website at http://www.implantsciences.com.

EVEN YEHUDA, Israel, March 3, 2014 /PRNewswire/ — Bluesphere Corp. (BLSP) (the “Company” or “Bluesphere”), an energy company that develops, manages and owns waste-to-energy projects, announced today its wholly-owned subsidiary has signed a Joint Venture Agreement with Alfa Eco Corporation. New York-based Alfa Eco is a leading private business group that consists of direct investment funds owning and managing assets in a range of industries, including energy in the United States and abroad. Alfa Eco has strategic partnerships in Bulgaria, Brazil, China, Kazakhstan, Mongolia, Russia, Sierra Leone, Switzerland, Ukraine and other countries.

Per the terms of the Joint Venture Agreement, Bluesphere and Alfa Eco will form a joint venture corporation jointly owned by the companies on a 50%/50% basis. Through the joint venture, the companies will develop turn-key and build-own-operate (“BOO”) waste-to-energy projects. Alfa Eco will provide turnkey and BOO projects with all required components in place (e.g., power purchase agreements, feedstock, etc.), while Bluesphere will arrange full financing and be the project integrator on the waste-to-energy projects.

“We are very pleased to form this joint venture corporation with Alfa Eco, a company which has resources and relationships that can support the development of numerous joint waste-to-energy projects in partnership with Bluesphere,” stated Bluesphere CEO Shlomi Palas. “Our ability to establish joint ventures, project financing, and long-term revenue contracts with energy industry leaders such as Alfa Eco is a testament to Bluesphere’s capabilities and reputation in the waste-to-energy market.”

Bluesphere generates electricity from biogas derived from organic waste, which is mostly food waste, and sells this electricity to leading electric companies through long-term power purchase agreements. Waste-to-energy is one of the fastest growing segments in the renewable energy markets. According to SBI Energy, the thermal and biological segments reached $6 billion in 2012 and will reach $29 billion by 2022.

For further information please contact Mark Radom at 972 52 798 0831 or info@bluespherecorporate.com.

About Alfa Eco Corporation
Alfa Eco was originally founded in 1989 as cooperative between Alfa Photo and ADP (Mikhail Fridman & Anatoly Potik). Since then, Mr. Potik re-developed the Alfa Eco Corporation. Alfa Eco is a leading private business group that consists of direct investment funds owning and managing assets in life science/healthcare, energy, metals & mining, construction development, agriculture, and education sectors in the United States and abroad. Alfa Eco has strategic partnerships in Bulgaria, Brazil, China, Kazakhstan, Mongolia, Russia, Sierra Leone, Switzerland, Ukraine and other countries. The strategy of Alfa Eco is targeted at the acquisition of assets in industries with a significant growth and consolidation potential. The company is also dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions.

About Bluesphere Corporation
Bluesphere Corporation is a company in the cleantech sector as a waste-to-energy project Integrator. Bluesphere develops waste-to-energy and other renewable energy projects. The Company aspires to become a key player in the global waste-to-energy and renewable energy markets. For further information please visit the Company’s website www.bluespherecorporate.com.

ROCKVILLE, Md.–(BUSINESS WIRE)–

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the company’s Board of Directors.

“We are very pleased to have Mark join Rexahn’s Board of Directors,” said Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer. “Mark’s extensive business and financing experience in the life sciences will be particularly important as we continue the development of our three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) for the treatment of multiple types of cancer.”

Dr. Chang Ahn, Ph.D., Chairman of the Board of Directors of Rexahn added, “Mark’s significant industry experience and leadership, which spans over more than 30 years in both pharmaceutical and smaller biotechnology companies, will be a tremendous asset to the Company. We welcome Mark to the Board of Directors and I am confident he will assist Rexahn in continuing to build value for our stockholders while we develop potentially life-saving treatments for patients.”

Mr. Carthy is the Managing Partner of Orion Equity Partners, LLC, a healthcare venture capital management and advisory firm co-founded by Mr. Carthy in 2008. Prior to founding Orion, Mr. Carthy was a Venture Partner and General Partner at Oxford Bioscience Partners, an early stage venture capital firm that provides equity financing and management assistance to companies within the life sciences, technology, energy and healthcare sectors. From 1998 until 2000, Mr. Carthy served as the Biotechnology Portfolio Manager at Morningside Ventures where he focused on early stage private equity investments. Previously, he was Chief Business Officer of Cubist Pharmaceuticals and Senior Director of Business Development at Vertex Pharmaceuticals. Mr. Carthy served as a member of the board of the New England Venture Capital Association from 2006 until 2013 and was listed on the Forbes Midas List in 2009 as one of the leading venture capitalists. He received a Bachelor of Chemical Engineering from the University College Dublin, Ireland, a Master of Science in Chemical Engineering from the University of Missouri and a Master of Business Administration from the Harvard Graduate School of Business Administration.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902), and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

VIENNA, Va.–(BUSINESS WIRE)–

Over the past three months, patient screening by participating hospitals and patient enrollment have steadily increased. In fact, we are even now seeing patient enrollment at centers that had not enrolled any patients under the prior Clinical Research Organization (CRO), inVentiv Health. CEL-SCI expects to see a further increase in the number of patients enrolled in the study at an accelerating pace as (i) the current centers finalize all logistical issues and (ii) an additional 50-60 centers are added throughout the world. Full enrollment of the planned 880 patients is expected by the end of 2015.

Per the study’s protocol design, four out of every seven patients enrolled are randomized to treatment with Multikine followed by the current standard of care (SOC) treatment, which is surgery plus radiotherapy or surgery plus concurrent radiochemotherapy. The remaining three patients receive SOC only – the control-treatment comparator group. In accordance with the protocol design, of the approximate 146 patients enrolled, an estimated 84 have already been dosed with Multikine.

The study’s Independent Data Monitoring Committee (IDMC), a committee of prominent physicians and scientists from around the world, already has completed two interim reviews of the unblinded trial data. Following each review, the IDMC concluded that the patient data raised no safety concerns and recommended that the Phase III study continue unmodified.

“We are very pleased with the acceleration of our study and based on what we are told by our current CROs Ergomed and Aptiv Solutions, we believe that both patient accrual and the study will continue to advance at a faster pace in the coming months,” stated CEL-SCI Chief Executive Officer Geert Kersten.

Most of the patient enrollment is under the control of Ergomed who has signed three co-development agreements for Multikine with CEL-SCI. The agreement concerning head and neck cancer calls for an investment by Ergomed of up to $10 million into the ongoing Phase III clinical trial. Ergomed will be repaid from future sales of Multikine, following regulatory approval.

Pompano Beach, Feb. 27, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced it is in the process of opening its first DS Laboratories retail store scheduled to open in the third quarter of 2014. The store, to be located in the metro Miami area, will showcase DS Healthcare’s line of products including its industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoo and conditioner. The move is part of the Company’s broader strategy as it continues to build the premier global brand in clinically proven personal care products.

DS Laboratories, the Company’s flagship brand is now sold in over 15 countries, helping address a global and underserved problem of hair loss. The Company’s first retail store in Miami will continue to increase brand awareness while adding to revenues and gross margins.

“Customers worldwide who have tried our products have a passion for them because they work. We believe our products, in particular our hair loss formulations, are the most effective on the market. With the opening of our first DS Laboratories retail store, we create an opportunity to increase our direct connection with consumers, leverage our marketing and advertising campaigns, and drive greater demand to the thousands of stores and salons that already carry our products,” stated DS Healthcare President and CEO Daniel Khesin.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group’s flagship brand, visit www.dslaboratories.com

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.